tbuckley/cabot-search huggingface dataset:
Abstract C55: The basic helix loop helix transcription factor E2A is associated with prostate cancer
Authors: Divya Patel, Jaideep Chaudhary
Journal: Cancer Research (2012)

Abstract Introduction: E2A (TCF3) is a multifunctional basic helix loop helix (bHLH), transcription factor. E2A regulates transcription of target genes by homo- or heterodimerization with other bHLH proteins such as MyoD, Mash, NeuroD and Id family of helix loop helix proteins. In general, E2A promotes cell differentiation, acts as a negative regulator of cell proliferation in normal cells and cancer cell lines and is required for normal B-cell development. Given the diverse biological pathways regulated/influenced by E2A little is known about its expression in cancer. Data mining approaches suggested that E2A is highly expressed in many cancers including prostate. Experimental design: E2A protein expression was investigated in clinical prostate tumor samples on high density tissue microarray slides by Immunohistochemistry (IHC). The expression of E2A in PCA cell lines DU145 and PC3 was temporarily silenced using E2A siRNA (sc-35245, Santa Cruz Biotechnology) and its effect on the Proliferation, cell cycle, apoptosis, mitochondrial membrane potential and caspase 3/7 activation was determined. The underlying mechanism of action of E2A was investigated by analyzing the expression of potential E2A regulated genes involved in cell cycle. Results: Consistent with increased E2A expression in prostate cancer suggested by meta-analysis, the E2A immunohistochemistry performed on prostate tissue microarrays demonstrated increased E2A expression in prostate cancer as compared to normal prostate. Silencing of E2A in prostate cancer cells DU145 and PC3 led to a significant reduction in proliferation due to G1 arrest that was in part mediated by increased CDKN1A(p21) and decreased Id1, Id3 and c-myc. E2A silencing in prostate cancer cell lines also resulted in increased apoptosis due to decrease in mitochondrial membrane permeability and increase in caspase 3/7 activity. Conclusion: Based on our results, we propose that E2A could be an upstream regulator of Id1 and c-Myc which are highly expressed in prostate cancer. These results for the first time demonstrate that E2A could in fact acts as a tumor promoter at least in prostate cancer. Acknowledgements: This study was supported by NIH/NCI RO1 CA128914 and NIH/NCRR/RCMI G12RR03062. Citation Format: Divya Patel, Jaideep Chaudhary. The basic helix loop helix transcription factor E2A is associated with prostate cancer [abstract]. In: Proceedings of the AACR Special Conference on Advances in Prostate Cancer Research; 2012 Feb 6-9; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2012;72(4 Suppl):Abstract nr C55.
Teenage measles outbreak shows shortcomings in Japan's immunisation programme
Authors: Peter Moszynski
Journal: BMJ (2007)

UK NEWS Scientists plead for right to create interspecies embryos, p1238 World NEWS US gro�p highlights symptoms of early o�arian cancer, p 12�� US gro�p highlights symptoms of early o�arian cancer, p 12�� bmj.com �itamin d from s�n e�pos�re may protect against solid cancers �itamin d from s�n e�pos�re may protect against solid cancers
Leaked report exposes mismatch in NHS staffing levels
Authors: Michael Day
Journal: BMJ (2007)

Huge disparities between projected numbers of NHS staff and the levels of personnel the health service actually needs—or can afford—have been shown in a government report leaked to the Health Service Journal . 

The draft NHS pay and workforce strategy for 2008-11 predicts a shortfall of 14 000 nurses and 1200 GPs but a surplus of 3200 consultants by 2010. 

As a partial solution the report suggests that a lower paid “sub-consultant” grade be created for doctors who have newly acquired their certificate of specialist training, but the suggestion has prompted an angry …
Local anaesthetic drugs in hospital practice
Authors: B. Dennison
Journal: BMJ (1983)

positive in the other 109 cases.The test may also be used to reposition catheters.2Though cranial deviation of a guidewire may indicate misplacement, the combination of head turning and supraclavicular pressure should prevent this complication, and any malpositions may be detected with the ausculatory test.In a subsequent consecutive series of 100 infraclavicular catheterisations I have used the head turning manoeuvre and the auscula- tory test, all catheters being correctly positioned before chest x ray examination.
In Utero Cardiac Gene Transfer via Intraplacental Delivery of Recombinant Adenovirus
Authors: Y. Joseph Woo, G. Praveen Raju, Judith L. Swain, Marc E. Richmond, Timothy J. Gardner, Rita J. Balice-Gordon
Journal: Circulation (1997)

Background The relationship among the maternal, placental, and uniquely shunted embryonic circulation was explored to provide access to the embryonic cardiovascular system in utero. Manipulation of gene expression in the developing heart would be particularly useful for studying the effects of altered gene expression on cardiac development and in the etiology of congenital cardiac anomalies. Methods and Results Dye studies demonstrated that intraplacental injection allows direct access to the embryonic cardiac and systemic circulation. To evaluate the efficacy of cardiac gene transfer using this approach, replication-deficient recombinant adenoviral vectors encoding luciferase or β-galactosidase as reporter genes were injected intraplacentally into embryonic day (E)12.5 murine embryos, an age at which the mass of the heart was observed to be large compared with other organs. Embryos were assayed for transgene expression at E15.5 and at birth. Survival rates at these times were similar among vector-injected and control groups. At E15.5 and at birth, luciferase activity within the heart was 9- and 23-fold higher, respectively, than in the remainder of the embryo, although levels of expression were generally lower at birth than during embryonic life. β-Galactosidase expression was observed within all regions of the embryonic heart and was localized to ≈15% of atrial and ventricular cells. Conclusions Intraplacental delivery of adenovirus at embryonic day 12.5 results in somatic gene transfer to the murine embryonic heart, which persists at least until birth. The combination of intraplacental injection to directly access the fetal coronary circulation and injection at E12.5 when the mass of the heart is large compared with other organs results in transgene expression in cardiac cells. Intraplacental injections early in embryonic life may thus be useful to study the effects of temporal manipulation of gene expression on cardiac development and disease.
Adhesion of human B cells to follicular dendritic cells involves both the lymphocyte function-associated antigen 1/intercellular adhesion molecule 1 and very late antigen 4/vascular cell adhesion molecule 1 pathways.
Authors: G Koopman, H K Parmentier, H J Schuurman, W Newman, C J Meijer, S T Pals
Journal: The Journal of Experimental Medicine (1991)

Presentation of antigen in the form of immune complexes to B lymphocytes by follicular dendritic cells (FDC) is considered to be a central step in the generation of memory B cells. During this process, which takes place in the microenvironment of the germinal center, B cells and FDC are in close physical contact. In the present study, we have explored the molecular basis of FDC-B cell interaction by using FDC and B cells derived from human tonsils. We found that FDC express high levels of the adhesion receptors intercellular adhesion molecule 1 (ICAM-1 [CD54]) and vascular cell adhesion molecule 1 (VCAM-1), while the B lymphocytes express lymphocyte function-associated antigen 1 (LFA-1 [CD11a/18]), very late antigen 4 (VLA-4 [CD49d], and CD44. Furthermore, we established that both the LFA-1/ICAM-1 and VLA-4/VCAM-1 adhesion pathways are involved in FDC-B lymphocyte binding, and therefore, these pathways might be essential in affinity selection of B cells and in the formation of B memory cells.
Cell therapy for liver disease: From liver transplantation to cell factory
Authors: Stuart J. Forbes, Sanjeev Gupta, Anil Dhawan
Journal: Journal of Hepatology (2015)

Work over several decades has laid solid foundations for the advancement of liver cell therapy. To date liver cell therapy in people has taken the form of hepatocyte transplantation for metabolic disorders with a hepatic basis, and for acute or chronic liver failure. Although clinical trials using various types of autologous cells have been implemented to promote liver regeneration or reduce liver fibrosis, clear evidence of therapeutic benefits have so far been lacking. Cell types that have shown efficacy in preclinical models include hepatocytes, liver sinusoidal endothelial cells, mesenchymal stem cells, endothelial progenitor cells, and macrophages. However, positive results in animal models have not always translated through to successful clinical therapies and more realistic preclinical models need to be developed. Studies defining the optimal repopulation by transplanted cells, including routes of cell transplantation, superior engraftment and proliferation of transplanted cells, as well as optimal immunosuppression regimens are required. Tissue engineering approaches to transplant cells in extrahepatic locations have also been proposed. The derivation of hepatocytes from pluripotent or reprogramed cells raises hope that donor organ and cell shortages could be overcome in the future. Critical hurdles to be overcome include the production of hepatocytes from pluripotent cells with equal functional capacity to primary hepatocytes and long-term phenotypic stability in vivo.
New US county level health rankings aim to spur the public
Authors: B. Roehr
Journal: BMJ (2010)

A new online database giving a detailed picture of health indicators in the United States down to the county level was unveiled in Washington, DC, on 17 February.

The researchers used five broad measures of health outcomes to rank each of the 3141 counties within its own state: premature mortality (years of potential life lost before the age of 75); the percentage of people who reported being in fair or poor health; the number of days people reported being in poor physical health; the number of days people reported being in poor mental health; and the percentage of low birthweight infants. …
Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells
Authors: S. Tamir Rashid, Sebastien Corbineau, Nick Hannan, Stefan J. Marciniak, Elena Miranda, Graeme Alexander, Isabel Huang-Doran, Julian Griffin, Lars Ahrlund-Richter, Jeremy Skepper, Robert Semple, Anne Weber, David A. Lomas, Ludovic Vallier
Journal: Journal of Clinical Investigation (2010)

Human induced pluripotent stem (iPS) cells hold great promise for advancements in developmental biology, cell-based therapy, and modeling of human disease. Here, we examined the use of human iPS cells for modeling inherited metabolic disorders of the liver. Dermal fibroblasts from patients with various inherited metabolic diseases of the liver were used to generate a library of patient-specific human iPS cell lines. Each line was differentiated into hepatocytes using what we believe to be a novel 3-step differentiation protocol in chemically defined conditions. The resulting cells exhibited properties of mature hepatocytes, such as albumin secretion and cytochrome P450 metabolism. Moreover, cells generated from patients with 3 of the inherited metabolic conditions studied in further detail (alpha1-antitrypsin deficiency, familial hypercholesterolemia, and glycogen storage disease type 1a) were found to recapitulate key pathological features of the diseases affecting the patients from which they were derived, such as aggregation of misfolded alpha1-antitrypsin in the endoplasmic reticulum, deficient LDL receptor-mediated cholesterol uptake, and elevated lipid and glycogen accumulation. Therefore, we report a simple and effective platform for hepatocyte generation from patient-specific human iPS cells. These patient-derived hepatocytes demonstrate that it is possible to model diseases whose phenotypes are caused by pathological dysregulation of key processes within adult cells.
Mental Health and Recovery in the Gulf Coast After Hurricanes Katrina and Rita
Authors: Richard H. Weisler, James G. Barbee, Mark H. Townsend
Journal: JAMA (2006)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Aetiology of hyperthyroidism. I.
Authors: R Hoffenberg
Journal: BMJ (1974)

Hyperthyroidism is not a single entity but at least 99% of cases are associated either with diffuse enlargement of the thyroid gland (Graves's disease) or with nodular goitre (Plummer's disease).Before considering the former, I should like to mention that some of the rare but no less interesting causes of hyper- thyroidism are listed in table I.
Antiviral Drugs Underused in US Patients for 2009 Influenza A(H1N1) Pandemic
Authors: Bridget M. Kuehn
Journal: JAMA (2011)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
What Goes On in a Practice?
Authors: DAVID PRAGER
Journal: Annals of Internal Medicine (1973)

Comments and Corrections1 June 1973What Goes On in a Practice?DAVID PRAGER, M.D.DAVID PRAGER, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-78-6-976_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Many residents and fellows enter specialty training programs with vague notions of what the clinical practice of their specialty will be like. Such speculation seems reasonable because the house staff is usually exposed to the specialty only in the hospital environment, not in private practice (1). There is, in fact, little recorded information about the composition of a specialty practice.In investigating this problem in the subspecialty of hematology, I analyzed my private practice, which is limited to hematology, to gain a more accurate disease-characterization of private practice (2). I hoped such characterization would enable the hematologist...References1. BURNUM J: What one internist does in his practice. Implications for the internist's disputed role and education. Ann Intern Med 78:437-444, 1973 LinkGoogle Scholar2. PRAGER D: An analysis of hematologic disorders presenting in the private practice of hematology. Blood 40:568-573, 1972 CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: DAVID PRAGER, M.D.Affiliations: Hematology-Oncology Associates, Inc. Allentown, Pennsylvania PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 June 1973Volume 78, Issue 6Page: 976-976KeywordsHematology and oncologySub-specialty care ePublished: 1 December 2008 Issue Published: 1 June 1973 PDF downloadLoading ...
A Comparison of Intracardiac and Intravenous Injections for the Measurement of Cardiac Output by the Dilution Technic
Authors: HAMPDEN C. LAWSON, OSCAR W. SHADLE, EVERETT S. COLEMAN, DOROTHY E. HOLTGRAVE
Journal: Circulation Research (1954)

Using H 3 P 32 O 4 and the dye T-1824 as labels, simultaneous injections were made into the right ventricle and into a peripheral vein, and cardiac output was calculated from the individual flow-dilution curves. When a discrepancy beyond the range expected from the use of the two labels occurred, the output from the central injection was always the larger (approximately one-third of the observations, in a small series). This may be attributable to progressive blood loss from sampling, since delayed intraventricular injections under comparable conditions, measure a similarly reduced cardiac output.
Proteinuria, lipoproteins and renal apolipoprotein deposits in uninephrectomized female analbuminemic rats
Authors: Jaap A. Joles, Harry van Goor, Branko Braam, Nel Willekes-Koolschijn, Eugène H.J.M. Jansen, Arie van Tol, Hein A. Koomans
Journal: Kidney International (1995)
Acute Hepatitis Associated with Jin Bu Huan
Authors: Graham M. Woolf
Journal: Annals of Internal Medicine (1995)

Letters15 April 1995Acute Hepatitis Associated with Jin Bu HuanGraham M. Woolf, MD and John M. Vierling, MDGraham M. Woolf, MDSearch for more papers by this author and John M. Vierling, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-122-8-199504150-00033 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:We appreciate the comments of Mr. Kaptchuk about our article. We concur that this herbal product contains a single active ingredient, L-tetrahydropalmatine, and therefore can be classified as a drug. We consulted with herbalists and botanists were aware that this product contained one active ingredient and who informed us that its origin was either the genus Stephania or Corydalis but was not Polygala as stated in the package insert. This mislabeling of the package insert was clearly stated in our article. Further, we commented on the fact that misidentification of the plant genus and an incorrect percentage of ... Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 15 April 1995Volume 122, Issue 8Page: 636KeywordsDrugsHepatitisSafety Issue Published: 15 April 1995 CopyrightCopyright © 1995 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
The Consult Guys - Twisted After Surgery: What Caused Torsades?
Authors: Geno J. Merli, Howard H. Weitz
Journal: Annals of Internal Medicine (2015)

Web Exclusives17 February 2015The Consult Guys - Twisted After Surgery: What Caused Torsades?FREEGeno J. Merli, MD and Howard H. Weitz, MDGeno J. Merli, MDSearch for more papers by this author and Howard H. Weitz, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/G15-3002 SectionsSupplemental MaterialAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail The Consult Guys bring a new perspective to the art and science of medicine with lively discussion and analysis of real-world cases and situations.For more videos from and information on The Consult Guys, visit www.annals.org/ConsultGuys. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: Disclosures: Geno J. Merli, MD, reports the following: Research grants/contracts: Bristol-Myers Squibb, Bayer, sanofi-aventis; Consultancies: Bristol-Myers Squibb, Bayer, sanofi-aventis. Howard H. Weitz, MD, reports that he has no financial relationships or interests to disclose. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byAnticoagulation? Antiplatelet? What's the Score?Jonathan Hager, MD 17 February 2015Volume 162, Issue 4Page: CG1KeywordsDisclosureResearch grantsResearch reporting guidelinesSurgery ePublished: 17 February 2015 Issue Published: 17 February 2015 Copyright & PermissionsCopyright © 2015 by American College of Physicians. All Rights Reserved.Loading ...
Neutrophil margination, sequestration, and emigration in the lungs of L-selectin-deficient mice.
Authors: N A Doyle, S D Bhagwan, B B Meek, G J Kutkoski, D A Steeber, T F Tedder, C M Doerschuk
Journal: Journal of Clinical Investigation (1997)

These studies tested the hypothesis that L-selectin plays a role in neutrophil traffic in the lungs, particularly in neutrophil margination, sequestration, and emigration, using L-selectin-deficient mice. No defect in neutrophil margination within either capillaries or arterioles and venules was observed in uninflamed lungs of L-selectin-deficient mice. The initial rapid sequestration of neutrophils within the pulmonary capillaries 1 min after intravascular injection of complement fragments was not prevented. In contrast, L-selectin did contribute to the prolonged neutrophil sequestration (> or = 5 min). Interestingly, neutrophil accumulation within noncapillary microvessels required L-selectin at both 1 and 5 min after complement injection. During bacterial pneumonias, L-selectin played a role in neutrophil accumulation within noncapillary microvessels in response to either Escherichia coli or Streptococcus pneumoniae and within capillaries in response to E. coli but not S. pneumoniae. However, L-selectin was not required for emigration of neutrophils or edema in response to either organism. These studies demonstrate a role for L-selectin in the prolonged sequestration of neutrophils in response to intravascular complement fragments, in the intracapillary accumulation of neutrophils during E. coli-induced pneumonia, and in the accumulation of neutrophils within noncapillary microvessels when induced by either intravascular complement fragments or
RANDOMISED TRIAL OF ALTERNATIVE FORMULATIONS OF ORAL POLIOVACCINE IN BRAZIL
Authors: P.A. Patriarca, G. Palmeira, J. Lima Filho, M. Tenorio Cordeiro, F. Laender, M.J. Couto Oliveira, M.C. De Souza Dantes, J.B. Risi, W.A. Orenstein
Journal: The Lancet (1988)